Related coverage linked through entity extraction aliases.
Jul 02, 2026
Telix gained FDA alignment to advance ProstACT Global Phase 3 into U.S. Part 2 for TLX591-Tx in mCRPC, with safety data from Part 1 deemed sufficient. The trial will combine the therapy with abiraterone, enzalutamide, or docetaxel, pending IND amendment review.
Jun 04, 2026
Telix Pharmaceuticals reported full-year 2025 revenue of US$803.8 million, up 56% year-over-year, driven by strong growth in its Precision Medicine segment and the successful U.S. launch of Gozellix. The company issued 2026 revenue guidance of US$950-970 million and advanced multiple regulatory filings and late-stage pipeline programs.
Mar 16, 2026
Telix Pharmaceuticals has submitted regulatory applications for TLX101-Px, a brain cancer imaging agent, to both the European Medicines Agency and the U.S. Food and Drug Administration, seeking approval for glioma diagnosis and treatment monitoring.
Feb 18, 2026
Telix Pharmaceuticals submitted a marketing authorization application in Europe for TLX101-Px, a glioma imaging agent, on February 18, 2026. The filing covers major European markets and a U.S. NDA submission will follow.
